Immunological and dermatological impact of progesterone

Gynecological Endocrinology

Volumn 15, Issue SUPPL. 6, 2001, Pages 18-21

  Huber, J ^a,b   Gruber, C ^a  

^a UNIV KLIN FÜR FRAUENHEILKUNDE   (Austria)

^b Universatatsklinik fur Anaesthesie   (Austria)

Author keywords

Langerhans cells; Matrix metalloproteinase activity; Progesterone; Vaginal immunity

Indexed keywords

MATRIX METALLOPROTEINASE; PROGESTERONE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ANIMAL; CELL COUNT; CUTANEOUS PARAMETERS; CYTOLOGY; DRUG EFFECT; EPITHELIUM CELL; FEMALE; HUMAN; IMMUNITY; INTRAVAGINAL DRUG ADMINISTRATION; LANGERHANS CELL; REVIEW; RISK FACTOR; SKIN; VAGINA;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADMINISTRATION, INTRAVAGINAL; ADULT; ANIMALS; CELL COUNT; EPITHELIAL CELLS; FEMALE; HUMANS; IMMUNITY; LANGERHANS CELLS; MATRIX METALLOPROTEINASES; PROGESTERONE; RISK FACTORS; SKIN; SKIN AGING; VAGINA;

EID: 0345563855     PISSN: 09513590     EISSN: None     Source Type: Journal    
DOI: 10.1080/gye.15.s6.18.21     Document Type: Article

References (12)

1. Wira CR, Richardson JM, Prabala R. Endocrine regulation of mucosal immunity: effect of sex hormones and cytokines on the afferent and efferent arms of the immune system in the female reproductive tract. In Ogra PL, Mestecky J, Lamm ME, et al., eds. Handbook of Mucosal Immunology. San Diego: Academic Press, 1994:705-19
2. Marx PA, Spira AI, Gettie A, et al. Progesterone implants enhance SIV vaginal transmission and early virus load. Nat Med 1996;2:1084-9
3. Hu J, Pope M, Brown C, O'Doherty U, Miller CJ. Immunophenotypic characterization of simian immunodeficiency virus-infected dendritic cells in cervix, vaginal and draining lymph nodes of rhesus monkeys. Lab Invest 1998;78:435-1
4. Martin HL Jr, Nyange PM, Richardson BA, et al. Hormonal contraception, sexually transmitted disease, and risk of heterosexual transmission of human immunodeficiency virus type 1. J Infect Dis 1998;178:1053-9
5. Li YY, McTiernan CF, Feldman AM. Interplay of matrix metalloproteinases, tissue inhibitors of metalloproteinases and their regulators in cardiac matrix remodeling. Cardiovasc Res 2000;46:214-24
6. Dollery CM, McEwan JR, Henney AM. Matrix metalloproteinases and cardiovascular disease. Circ Res 1995;77:836-68
7. Spinale FG, Tomita M, Thomas CV, Walker JD, Mukkherjee R, Hebbar L. Time-dependent changes in matrix metalloproteinase activity and selective upregulation in LV myocardium from patients with end-stage dilated cardiomyopathy. Circ Res 1998;82:482-95
8. Li YY, Feng Q, Kadokami T, McTiernan CF, Watkins SC, Feldman AM. Myocardial extracellular matrix remodeling in transgenic mice overexpressing tumor necrosis factor-a can be modulated by anti-tumor necrosis factor-a therapy. Proc Natl Acad Sci USA 2000;97:12746-51
9. Gunja Smith Z, Morales AR, Romanelli R, Woessner JF. Remodeling of human myocardial collagen in idiopahtic dilated cardiomyopathy: role of metalloproteinase and pyridinoline cross links. Am J Physiol 1996;148:1639-48
10. Li YY, Feldman AM, Sun Y, McTiernan CF. Differential expression of tissue inhibitors of metalloproteinase activity in the failing human heart. Circulation 1998;98:1728-34
11. Thomas CV, Coker ML, Zellner JL, Handy JR, Crumbley AJ III, Spinale FG. Increased matrix metalloproteinase activity and selective upregulation in LV myocardium from patients with end-stage dilated cardiomyopathy. Circulation 1997;97:1708-15
12. Spinale FG, Coker ML, Heung LJ, et al. Matrix metalloproteinase induction/activation system exists in the human left ventricular myocardium and is upregulated in the heart failure. Circulation 2000;102:1944-9